Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308),
LifeArc Seed Fund Makes £1.5million Investment in Caldan Therapeutics to Develop Novel Treatments for Metabolic Diseases
LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of
Epidarex Co-founder and Managing Partner Kyp Sirinakis Joins TEDCO’s New Task Force for Women Entrepreneurs
Epidarex co-founder and managing partner Kyp Sirinakis has joined TEDCO’s new Task Force for Women Entrepreneurs. The task force is dedicated to the recruitment, funding,
Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease
Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease
Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
Top-line Data Anticipated in December 2019 CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused
NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors Appoints Don Nicholson as Board Chairman and Kevin Lee as
IGEM Therapeutics Appoints Dr David Chiswell as a Non-Executive Chairman
Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM’s Board London, 9 April 2019 – IGEM Therapeutics (IGEM),